Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Alkermes plc Ordinary Shares (ALKS)

NASDAQ: ALKS · Pharmaceutical Preparations · Dublin 4, L2

Our rating: Neutral

Call changed from Cautious to Neutral at $45.89, moderate conviction, November 4, 2026.

Breaks if: The Neutral call turns Cautious if the full-year revenue run rate falls more than 10% YoY over the next twelve months, or if annual free cash flow drops below $300M in the next reported annual period — either would signal structural franchise deterioration that the current FCF-based valuation does not price in. It turns Positive if revenue returns to growth of at least 3% YoY across two consecutive quarterly filings, confirming the recent decline was transitory rather than the leading edge of a steeper trend.

Key figures

Market value$7.6B
Revenue, last 12 months$1.8B
Net income, last 12 months−$351000.00
Free cash flow, last 12 months$227M
Price to earningsn/a
Free cash flow yield3.0%
Dividend yield0.0%
Operating margin3.7%
Return on equity−0.0%
Beta to the S&P 5000.63
Volatility, annualized36.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$480M21.8%$0.09$90M
June 30, 2026$496M27.0%$0.00$137M
March 31, 2026$393M28.2%$-0.40−$170M
December 31, 2025$385M−10.6%$0.29$170M
September 30, 2025$394M4.2%$0.49$84M
June 30, 2025$391M−2.1%$0.52$137M
March 31, 2025$307M−12.5%$0.13$89M
December 31, 2024$430M13.9%$0.87$181M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 50 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.